🔎 Trials Near Me

Domov › Prekomerna telesna teža › South Carolina

Klinične študije za Prekomerna telesna teža v South Carolina

35 študij za Prekomerna telesna teža išče udeležence na lokacijah v South Carolina.

Mesta v South Carolina

Uradno besedilo študije (angleško)

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  • Spartanburg Medical Research, Spartanburg
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • Prisma Health-Ped Endo, Greenville
  • Coastal Carolina Research Ctr, North Charleston
Vključevanje udeležencevFaza 3
Starost 8–18 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07253285

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  • Tribe Clinical Research, Greenville
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07685808

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Medical Uni of SC Charleston, Charleston
  • Coastal Carolina Research Ctr, North Charleston
  • Hillcrest Clinical Research, Simpsonville
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • Medical University Of South Carolina, Charleston
  • Hillcrest Clinical Research, Simpsonville
  • Spartanburg Medical Research, Spartanburg
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07668414

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • Care Access - Mauldin, Mauldin
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07794579

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastroenterology Associates - Patewood, Greenville
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Coastal Pediatric Associates, Charleston
  • Medical University of South Carolina Children Hospital - PIN, Charleston
Vključevanje udeležencevFaza 3
Starost 6–17 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Gastroenterology Associates - Patewood, Greenville
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Accellacare - Mt Pleasant, Mt. Pleasant
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • Trial Management Associates, Myrtle Beach
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Bogan Sleep Consultants, Columbia
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Accellacare Charleston, Mt. Pleasant
Vključevanje udeležencevFaza 3
Starost 45–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Tribe Clinical Research, LLC, Greenville
  • Accellacare - Mt Pleasant, Mt. Pleasant
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07321886

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Tribe Clinical Research, LLC, Greenville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Bluffton
  • AURORA-1 Clinical Site, Clemson
  • AURORA-1 Clinical Site, Columbia
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Bluffton
  • AURORA-2 Clinical Site, Clemson
  • AURORA-2 Clinical Site, Columbia
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Coastal Carolina Research Center, North Charleston
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351058

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Trial Management Associates, Myrtle Beach
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Greer
Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
Starost 18–79 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  • Spartanburg Medical Research, Spartanburg
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07770841

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

  • Bogan Sleep Consultants, LLC, Columbia
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07571109

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Tribe Clinical Research, LLC, Greenville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06143956

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

  • Coastal Carolina Res Ctr, North Charleston
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07745504

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Spartanburg
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Tribe Clinical Research LLC Dba Mountain View Clinical Research, Greenville
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Mauldin
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284875

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Greer
Vključevanje udeležencevFaza 3
Starost 18–79 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT07654361

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

  • Coastal Carolina Research Ctr, North Charleston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 25. jun. 2026 · NCT07607587

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

  • Monroe Biomedical Research, North Charleston
Vključevanje udeležencevFaza 2
Starost 18–60 · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT07570758

Efficacy of Center-based Childcare to Mitigate Unhealthy Weight Gain in Preschoolers From Low-income Households During the Summer

  • University of South Carolina, Columbia
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 3–5 · Vsi spoli · Posodobljeno 11. jun. 2026 · NCT07583459

Pistachio Snacking and Metabolic Flexibility

  • Public Health Research Center: Clinical Exercise Research Center, Columbia
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 25–45 · Vsi spoli · Posodobljeno 14. jan. 2026 · NCT07340125

Optimal Digital Weight Loss Treatment for Rural Individuals

  • University of South Carolina, Columbia
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 23. dec. 2025 · NCT06105957

Fueling Strong Hearts for a Strong South Carolina

  • Pee Dee Research and Education Center, Florence
Vključevanje udeležencev
Starost 45–80 · Vsi spoli · Posodobljeno 26. avg. 2025 · NCT07140952

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.